In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

Methods: 1. For monoclonal antibodies targeting Aβ clearance, we selected seven: Aducanumab, Bapineuzumab, Crenezumab, Donanemab, Gantenerumab, Lecanemab, and Solanezumab. Our data is derived from ...

(RTTNews) - Biogen Inc. (BIIB), a biotechnology company and Eisai Co., Ltd. On Friday provided an update on the regulatory review of lecanemab as a treatment for early Alzheimer's disease or AD in ...

Viehbacher, "Biogen") announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ... of amyloid-beta (Aβ). Since July 2020 the ...

Kelley agreed, noting that many patients at UT Southwestern are choosing donanemab over lecanemab now. Some clinicians said they would want to evaluate plaque level via PET scan before deciding ...

The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

2021; Yamazaki et al., 2019). In late-onset AD, which occurs sporadically after the age of 65, the impairment of amyloid β-protein (Aβ) clearance mechanisms seems to be a primary factor in the ...